Alzheimer’s/PD/DLB biomarker and treatment momentum
Key Questions
What blood-based biomarkers are advancing for Alzheimer's detection in primary care?
Blood tests like p-tau217/GFAP and a new 34-circRNA signature are moving toward primary care use, with the latter outperforming pTau217. A new commercial tau tangle test (eMTBR-Tau) has launched, and p-tau217 shows strong predictive value (AUC 0.88) for 10-year AD risk.
How effective was diranersen in the AAIC 2026 trial?
Diranersen missed its primary endpoint but achieved 50-65% tau reduction and 26% CDR-SB slowing at 60mg in Phase 2, prompting Biogen to advance to Phase 3. This provides early evidence that tau targeting can slow cognitive decline.
What non-drug interventions show promise for Alzheimer's?
The Cerezen device demonstrated 78% cognitive gains, while 40 Hz GENUS light/sound therapy reduced pTau217 and slowed decline in pilots, with FDA approval targeted for 2027. Multidomain lifestyle interventions also show small cognitive benefits per meta-analysis.
Are p-tau217 biomarkers deterministic for Alzheimer's progression?
No, a JAMA analysis of 2,684 participants found 62% with very high p-tau217 did not decline over 5.4 years, indicating they are risk predictors rather than deterministic. However, they improve diagnostic accuracy from 65% to 93% in primary care settings.
What new treatments target tau or related mechanisms?
SORLA protein boosting suppressed tau tangles in mice, while RI-AG03 showed first human cognitive signals as a tau aggregation inhibitor. Pepinemab targets astrocytes via SEMA4D, with Phase 2b planned.
How might high-performing blood tests impact Alzheimer's diagnosis?
Modeling indicates they could reduce diagnostic wait times by 35%, and real-world data shows 82.5% of early AD patients stable or improved on lecanemab. Subcutaneous formulations and at-home starter doses have also been approved to ease access.
What challenges exist for biomarker access in Europe?
Over 80% of European health systems lack access to advanced biomarker testing, raising policy questions for disease-modifying therapy rollout. Lucent Diagnostics and Tempus are collaborating on care gap programs to expand blood-based testing.
What links sleep issues to Alzheimer's pathology?
Sleep loss is tied to microglia overactivity, with long sleep duration linked to elevated tau; KY scientists identified mechanisms and potential interventions. Sleep EEG with AI can detect early AD and identify biological subgroups.
Blood tests (p-tau217/GFAP, circRNAs) advancing to primary care; first commercial tau tangle blood test launched. New 34-circRNA signature outperforms pTau217. Diranersen tau ASO Phase 2 CELIA showed 50-65% tau reduction and 26% CDR-SB slowing at 60mg. Voyager's VY1706 tau gene therapy IND cleared, first-in-human imminent. 40 Hz GENUS light/sound therapy pilot shows cognitive slowing; FDA approval expected June 2027. Real-world lecanemab data: 82.5% stable/improved. ProMIS Neurosciences' PMN310 shows no ARIA-E across all genotypes. New: pTau217 predicts 5x-11x increased dementia risk in Parkinson's disease. New: 3D genome disruption identified as novel layer of Alzheimer's pathology. New: Microglial resilience study identifies transition from inflammatory to tau-associated state. New: Lucent Diagnostics and Tempus collaborate to expand blood-based testing. New: Three gene variants (CCNG1) may accelerate or delay Alzheimer's onset. New: LM11A-31 shows network connectivity changes. New: Tazbentetol shows durable cognitive benefit through 84 weeks. New: Gut microbiome changes in preclinical Alzheimer's. New: Yale team resolves atomic structure of toxic amyloid beta oligomers. New: NHS in talks to roll out Alzheimer's drug; Australia pTau217 blood test achieves 90% accuracy with 18-minute turnaround. New: Biogen CEO remains cautious despite diranersen tau validation. New: Phase II trial of intranasal insulin in PD shows safety and cognitive signal. New: Coal-fired power plant proximity associated with 72.9% increased odds of AD neuropathology. New: Alnylam's mivelsiran shows no ARIA in Down syndrome AD Phase 2; tau-targeting RNAi ALN-5288 enters Phase 1. New: Vocal biomarkers standardized for early AD detection via AI. New: Behavioral symptoms as early signs of Alzheimer's highlighted. New: Rutgers launches first U.S. Alzheimer's study for South Asians, highlighting distinct risk profiles. New: Kisunla (donanemab) rollout expanding to local clinics (Topeka). New: Mitochondrial plaques identified as novel Alzheimer's target (U of M, Nature Neuroscience). New: Policy blueprint from Alzheimer's Research UK calls for systemic readiness. New: Good overview of Alzheimer's blood test landscape from AAIC, covering approved tests and real-world recall issues. New: Donanemab dosing tweak (slower titration) cuts ARIA-E by a third, especially in ApoE4 homozygotes (57% to 24%); dexamethasone reduces infusion reactions; ultra-fast MRI lowers monitoring burden; long-term extension hints at annual maintenance dosing. New: PMN310 shows 0% ARIA-E even in APOE4 carriers. New: VY1706 tau gene therapy preclinical data clean. New: Remlifanserin Fast Track for Alzheimer's psychosis. New: Cannabinoid for agitation shows efficacy but higher SAEs. New: XPro1595 for TBI-Alzheimer link. New: Modified anti-Aβ antibodies review: BBB-penetrating bispecifics, glycosylation engineering, ADCs. The field is moving toward biomarker-guided personalized treatment, as discussed in a recent expert synthesis. New: J-ADNI analysis confirms CDR-GS and MMSE as strong predictors of DMT eligibility windows in Japanese Alzheimer's patients, with MCI patients staying eligible longer than AD. New: Systemic and brain frailty modulate anti-amyloid mAb response, informing patient selection. New: ML-based diagnostic tool for neurodegenerative diseases aids early detection. New: GLP-1/GIP agonists (incretin mimetics) show preclinical amyloid/tau reduction but weak human data; liraglutide's BACE1 suppression noted. New: Gut microbiome shifts in preclinical Alzheimer's identified. New: Valiltramiprosate (oral amyloid oligomer inhibitor) shows rapid p-tau217 reduction in APOE4/4 homozygotes, no ARIA, promising for high-risk MCI. New: Microglia overactivation, not plaques, drives sleep loss in AD; depleting microglia restores sleep in mice, opening neuroinflammation-targeted therapy. New: Rapid Alzheimer's testing in Australia (Roche platform) delivers pTau217/pTau181/ApoE4 in 18 minutes, enabling earlier DMT eligibility. New: Eisai launches LEQEMBI in India as first DMT for early AD, expanding global access. New: Centiloid scale explainer reinforces precision imaging for patient selection. New: Venetoclax (BCL-2 inhibitor) shows preclinical anti-Aβ42 aggregation activity, potential repurposing for AD. New: India DMT market heats up with Leqembi at ₹21,682/vial vs donanemab at ~₹97,000/vial; Eisai touts lower ARIA, Lilly fixed-dose convenience. New: Australia blood test breakthrough moves to clinical implementation with TGA approval and dedicated centre, though cannot predict symptom onset. New: Specific CVD subtypes, especially hypotension, associated with Alzheimer's risk, with genetic overlap at 19q13.32, 17q21.31, 11p11.2, reinforcing vascular-AD axis.